停止 AF 首次批准后研究
STOP AF 首次批准后研究,Cryo Global Registry 的附录
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
研究概览
详细说明
The STOP AF First Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The STOP AF First PAS is a prospective, global, multi-center, observational trial. The purpose of the study is to describe long-term clinical performance and safety data in the recurrent symptomatic paroxysmal AF population treated with Arctic Front™ and Freezor™ MAX Families of cardiac cryoablation catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System) as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. This PAS is a condition of the pre-market approval order (P100010/S110) by the U.S. Food and Drug Administration.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Alaska
-
Anchorage、Alaska、美国、99508
- Alaska Heart Institute
-
-
Connecticut
-
Stamford、Connecticut、美国、06905-5522
- Cardiology Associates of Fairfield County
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater、Florida、美国、33756
- BayCare Medical Group Cardiology
-
Davie、Florida、美国、33328
- Heart Rhythm Solutions
-
-
Iowa
-
West Des Moines、Iowa、美国、50266
- Iowa Heart
-
-
Massachusetts
-
North Dartmouth、Massachusetts、美国、02747
- Southcoast Health System
-
-
Michigan
-
Detroit、Michigan、美国、48202-2608
- Henry Ford Heart & Vascular
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- The Lindner Research Center
-
-
Tennessee
-
Germantown、Tennessee、美国、38138
- Stern Cardiovascular Foundation
-
-
Texas
-
Dallas、Texas、美国、75231
- Texas Health Research and Education Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ cardiac cryoablation catheter System.
描述
Inclusion Criteria:
- Subject has been diagnosed with symptomatic paroxysmal AF
- Subject is ≥ 18 years of age or minimum age as required by local regulations
- Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.
- Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements
Exclusion Criteria:
History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1
. Subjects under the following conditions may be included in the study:
-
Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of <4 weeks prior to the index PVI procedure)
-
Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
-
A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.
- Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)
- Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
- Subject with exclusion criteria required by local law
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)
大体时间:36 months
|
Estimate the 36-month freedom from Atrial Fibrillation (AF) /atrial flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ cardiac cryoablation catheter System. |
36 months
|
|
Freedom from Primary Safety Events
大体时间:12 months
|
Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ cardiac cryoablation catheter System through 12-months. |
12 months
|
合作者和调查者
调查人员
- 研究主任:Khaldoun Tarakji, MD、Medtronic CAS Chief Medical Officer
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.